Logo EURACAN - European Network For Rare Adult Solid Cancer Logo European Reference Network TO ALL EURACAN GUIDELINES
Welcome to the EURACAN’s Clinical Practice Guidelines
Click to open the video

Bone sarcomas: ESMO–PaedCan–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up

picture - Introduction


  • Expert Center

  • MultiDisciplinary Team

These ESMO–EURACAN Clinical Practice Guidelines cover different subtypes of bone sarcomas

Osteosarcoma (OS) and Ewing sarcoma (ES) have a relatively high incidence in the second decade of life, whereas chondrosarcoma (CS) is more common in older age[2–4].

STSs are covered by ESMO–EURACAN Clinical Practice Guidelines on Soft tissue and visceral sarcomas
GISTs are covered by ESMO–EURACAN Clinical Practice Guidelines on Gastrointestinal stromal tumours

  • Multidisciplinary approach by sarcome expert  in a Multi disciplinary Team is mandatory in all cases.
  • Management of bone sarcomas should be carried out in reference centres for sarcomas and/or within reference networks

see page on reference networks and centres



Casali PG, Bielack S, Abecassis N, et al. Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl 4):iv79-iv95. doi:10.1093/annonc/mdy310


P. G. Casali‡1, S. Bielack‡2, N. Abecassis3, H.T. Aro4, S. Bauer5, R. Biagini6, S. Bonvalot7, I. Boukovinas8, J. V. M. G. Bovee9, B. Brennan10, T. Brodowicz11, J. M. Broto12, L. Brugières13, A. Buonadonna14, E. De Álava15, A. P. Dei Tos16, X. G. Del Muro17, P. Dileo18, C. Dhooge19, M. Eriksson20, F. Fagioli21, A. Fedenko22, V. Ferraresi6, A. Ferrari23, S. Ferrari24, A. M. Frezza25, N. Gaspar13, S. Gasperoni26, H. Gelderblom27, T. Gil28, G. Grignani29, A. Gronchi1, R. L. Haas30, B. Hassan31, S. Hecker-Nolting2, P. Hohenberger32, R. Issels33, H. Joensuu34, R. L. Jones35, I. Judson36, P. Jutte37, S. Kaal38, L. Kager39, B. Kasper32, K. Kopeckova40, D. A. Krákorová41, R. Ladenstein39, A. Le Cesne13, I. Lugowska42, O. Merimsky43, M. Montemurro44, B. Morland45, M. A. Pantaleo46, R. Piana21, P. Picci24, S. Piperno-Neumann7, A. L. Pousa47, P. Reichardt48, M. H. Robinson49, P. Rutkowski42, A. A. Safwat50, P. Schöffski51, S. Sleijfer52, S. Stacchiotti25, S. J. Strauss18, K. Sundby Hall53, M. Unk54, F. Van Coevorden55, W.T.A. van der Graaf35,38,55, J. Whelan18, E. Wardelmann56, O. Zaikova57 & J. Y. Blay58, on behalf of the ESMO Guidelines Committee, PaedCan and ERN EURACAN*

*Correspondence to: ESMO Guidelines Committee, ESMO Head Office, Via Ginevra 4, 6900 Lugano, Switzerland. E-mail: clinicalguidelines@esmo.org
†Approved by the ESMO Guidelines Committee, PaedCan and EURACAN: August 2018.
‡Contributed equally.



2. Whelan J, McTiernan A, Cooper N et al. Incidence and survival of malignant bone sarcomas in England 1979-2007. Int J Cancer 2012; 131: E508–E517.
3. Valery PC, Laversanne M, Bray F. Bone cancer incidence by morphological subtype: a global assessment. Cancer Causes Control 2015; 26: 1127–1139.
4. Van den Berg H, Kroon HM, Slaar A, Hogendoorn P. Incidence of biopsy-proven bone tumors in children: a report based on the Dutch pathology registration “PALGA”. J Pediatr Orthop 2008; 28: 29–35.


Patient’s typology